title: Functional epigenomics approach to identify methylated candidate tumour suppressor genes in renal cell carcinoma.
abstract: Promoter region hypermethylation and transcriptional silencing is a frequent cause of tumour suppressor gene (TSG) inactivation in many human cancers. Previously, to identify candidate epigenetically inactivated TSGs in renal cell carcinoma (RCC), we monitored changes in gene expression in four RCC cell lines after treatment with the demethylating agent 5-azacytidine. This enabled us to identify HAI-2/SPINT2 as a novel epigenetically inactivated candidate RCC TSG. To identify further candidate TSGs, we undertook bioinformatic and molecular genetic evaluation of a further 60 genes differentially expressed after demethylation. In addition to HAI-2/SPINT2, four genes (PLAU, CDH1, IGFB3 and MT1G) had previously been shown to undergo promoter methylation in RCC. After bioinformatic prioritisation, expression and/or methylation analysis of RCC cell lines+/-primary tumours was performed for 34 genes. KRT19 and CXCL16 were methylated in RCC cell lines and primary RCC; however, 22 genes were differentially expressed after demethylation but did not show primary tumour-specific methylation (methylated in normal tissue (n=1); methylated only in RCC cell lines (n=9) and not methylated in RCC cell lines (n=12)). Re-expression of CXCL16 reduced growth of an RCC cell line in vitro. In a summary, a functional epigenomic analysis of four RCC cell lines using microarrays representing 11 000 human genes yielded both known and novel candidate TSGs epigenetically inactivated in RCC, suggesting that this is valid strategy for the identification of novel TSGs and biomarkers.
authors.affiliation: Cancer Research UK Renal Molecular Oncology Group, University of Birmingham, Birmingham B15 2TT, UK.
authors.forename: M R
authors.initials: MR
authors.lastname: Morris
authors.forename: D
authors.initials: D
authors.lastname: Gentle
authors.forename: M
authors.initials: M
authors.lastname: Abdulrahman
authors.forename: N
authors.initials: N
authors.lastname: Clarke
authors.forename: M
authors.initials: M
authors.lastname: Brown
authors.forename: T
authors.initials: T
authors.lastname: Kishida
authors.forename: M
authors.initials: M
authors.lastname: Yao
authors.forename: B T
authors.initials: BT
authors.lastname: Teh
authors.forename: F
authors.initials: F
authors.lastname: Latif
authors.forename: E R
authors.initials: ER
authors.lastname: Maher
mesh_terms: D002292:Carcinoma, Renal Cell / Q000235:genetics*; D045744:Cell Line, Tumor; D000075743:Chemokine CXCL16; D019743:Chemokines, CXC / Q000235:genetics / Q000378:metabolism; D019175:DNA Methylation; D044127:Epigenesis, Genetic; D015972:Gene Expression Regulation, Neoplastic; D052138:Genes, Neoplasm; D016147:Genes, Tumor Suppressor; D023281:Genomics / Q000379:methods*; D006801:Humans; D007680:Kidney Neoplasms / Q000235:genetics*; D014411:Neoplastic Stem Cells / Q000378:metabolism; D011401:Promoter Regions, Genetic; D051116:Receptors, Scavenger / Q000235:genetics / Q000378:metabolism; D014162:Transfection
chemical_list: C423727:CXCL16 protein, human; D000075743:Chemokine CXCL16; D019743:Chemokines, CXC; D051116:Receptors, Scavenger